Overview of Regulatory Guidelines Related to Methods and Models for Small Populations.

Authors

Laurens Sluijterman, Letao Li, Kristin E Karlsson, Vincent Damotte, Sarah Zohar, Kit Roes, Joanna IntHout

Published in

Clinical pharmacology and therapeutics. Oct 13, 2026. Epub Oct 13, 2026.

Abstract

This paper provides an overview of approaches and related guidelines from the EMA, FDA, and ICH that are relevant for obtaining clinical evidence for small populations to support regulatory decision making. The approaches are grouped into three categories: (1) maximizing the attainable sample size, (2) adapting the trial design to deal with a small sample size, and (3) including external information, while also examining the role of modeling. Guidelines for clinical trials, guidelines specifically for small populations, as well as guidelines that include the use of modeling to support clinical evidence were included in the review. A recurring theme throughout the guidelines is the critical importance of the clinical context, affecting both the evidentiary standard and which approaches and models are acceptable. Two key gaps were identified: (1) guidance on Bayesian approaches is limited, and (2) there is no clear guidance on how to synthesize evidence across different modalities, such as trial results and Real-World Data, from both a practical and regulatory perspective.

PMID:
42867201
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.